NEW YORK, August 22, 2017 /PRNewswire/ --
If you want a Stock Review on OPGN, TEAR, TROV, or PRAH then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. IBISWorld reported last June that, in the five years to 2022, the Diagnostic and Medical Laboratories industry will benefit from scientific advances that yield new and improved service capabilities, coupled with the aging US population requiring more laboratory testing and diagnostic imaging services. Today, DailyStockTracker.com presents for review four Medical Labs and Research companies, particularly, OpGen Inc. (NASDAQ: OPGN), TearLab Corp. (NASDAQ: TEAR), TrovaGene Inc. (NASDAQ: TROV), and PRA Health Sciences Inc. (NASDAQ: PRAH). Learn more about these stocks by downloading their comprehensive and free reports from DailyStockTracker.com member's area at:
On Monday, shares in Gaithersburg, Maryland headquartered OpGen Inc. surged 11.08%, ending the day at $0.27. The stock recorded a trading volume of 3.91 million shares, which was above its three months average volume of 1.48 million shares. The Company's shares are trading below their 50-day moving average by 40.40%. Moreover, shares of OpGen, which engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide, have a Relative Strength Index (RSI) of 33.26.
On August 08th, 2017, OpGen reported financial and operational results for the three and six months ended June 30th, 2017. For Q2 2017, total revenue was $0.7 million; operating expenses were $4.9 million; and net loss was $4.2 million. For the six months ended June 30th, 2017, total revenue was $1.5 million; operating expenses were $10.6 million; and net loss was $9.2 million. OPGN complete research report is just a click away at:
Shares in San Diego, California headquartered TearLab Corp. ended the day 0.62% higher at $1.61 with a total trading volume of 125,882 shares. The stock is trading below its 50-day moving average by 18.30%. Shares of the Company, which operates as an in-vitro diagnostic company in the US, have an RSI of 38.31.
On August 14th, 2017, TearLab reported its consolidated financial results for the quarter ended June 30th, 2017. For Q2 2017, total revenue was $7.0 million; gross profit was $3.9 million; total operating expenses were $6.7 million; and net loss was $3.9 million. Cash position was $10.2 million as of June 30th, 2017. The complimentary report on TEAR can be downloaded at:
At the close of trading on Monday, shares in San Diego, California headquartered TrovaGene Inc. finished 1.17% lower at $0.82 with a total trading volume of 281,646 shares. The stock has advanced 5.67% over the previous three months. The Company's shares are trading below their 50-day moving average by 18.16%. Additionally, shares of TrovaGene, which focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the US, have an RSI of 40.83.
On August 16th, 2017, TrovaGene announced positive data from a preclinical in-vivo study examining the combination of their PLK1 inhibitor, PCM-075, with a leading investigational FLT3 Inhibitor. This FLT3 mutant xenograft model shows PCM-075 in combination with Quizartinib resulted in 96% tumor growth inhibition versus monotherapy with Quizartinib (81%) or PCM-075 (76%). Sign up for your complimentary research report on TROV at:
PRA Health Sciences
Raleigh, North Carolina headquartered PRA Health Sciences Inc.'s shares recorded a trading volume of 531,238 shares at the end of yesterday's session. The stock closed the day 0.47% higher at $75.11. The Company's shares have advanced 5.68% in the previous three months and 36.27% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.32% and 17.20%, respectively. Additionally, shares of the Company, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have an RSI of 50.04.
On August 14th, 2017, PRA Health Sciences announced the appointment of Alexander G. Dickinson to its Board of Directors. Dr. Dickinson is the Executive Chairman of ChromaCode, a private clinical diagnostics company. Previously, he was the Senior Vice President of Strategic Initiatives at Illumina, Inc., where his responsibilities included working with national governments and large institutions to develop precision medicine programs for healthcare systems.
On August 17th, 2017, research firm Raymond James initiated an 'Outperform' rating on the Company's stock, with a target price of $89 per share. Get free access to your research report on PRAH at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA